Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212009 | 0.89 | TSHR (0.45) | TSHRALDH1A1HPGDTP53HIF1A | |
| SCHEMBL11428322 | 0.88 | TSHR (0.41) | TSHRALDH1A1HPGDTP53HIF1A | |
| SCHEMBL12285539 | 0.86 | TSHR (0.42) | TSHRALDH1A1HPGDTP53HIF1A | |
| SCHEMBL14509173 | 0.85 | TSHR (0.39) | TSHRALDH1A1HPGDTHRB | |
| SCHEMBL18215276 | 0.84 | — | — | |
| SCHEMBL34386 | 0.84 | — | — | |
| SCHEMBL18215270 | 0.84 | — | — | |
| SCHEMBL28876418 | 0.84 | TSHR (0.41) | TSHRALDH1A1HPGDTP53HIF1A | |
| SCHEMBL12285537 | 0.83 | TSHR (0.40) | TSHRALDH1A1HPGDTP53HIF1A | |
| SCHEMBL10445967 | 0.83 | TSHR (0.47) | TSHRALDH1A1HPGDTP53HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134753-A1 | BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES | THE JOHNS HOPKINS UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-20180028455-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | disclosed |
| US-9802984-B2 | Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802984-B2 | Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9717694-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717694-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170143639-A1 | NANOCOMPOSITES OF GOLD AND POLYMERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143639-A1 | NANOCOMPOSITES OF GOLD AND POLYMERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160374949-A9 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160122390-A1 | A BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122390-A1 | A BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-05-05 | — | — | US | disclosed |
| US-20150272900-A1 | Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics | THE JOHNS HOPKINS UNIVERSITY | 2015-10-01 | — | — | US | disclosed |
| US-20150272900-A1 | Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics | THE JOHNS HOPKINS UNIVERSITY | 2015-10-01 | — | — | US | disclosed |
| US-20140294909-A1 | NANOCOMPOSITES OF GOLD AND POLYMERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140294909-A1 | NANOCOMPOSITES OF GOLD AND POLYMERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2013056113-A1 | NANOCOMPOSITES OF GOLD AND POLYMERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20120114759-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114759-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374949-A9 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | VEGFA, IAPP, FLT1 | TSHR 2490/4885ALDH1A1 4007/4885HPGD 1920/4885 |
| US-20160122390-A1 | A BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES | VEGFA, LRRFIP1, FLT1 | TSHR 2524/4885ALDH1A1 3688/4885HPGD 3420/4885 |
| US-20150272900-A1 | Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics | DNMT3L, DBNL, HNRNPL | TSHR 2581/4885ALDH1A1 2087/4885HPGD 3928/4885 |
| US-20170143639-A1 | NANOCOMPOSITES OF GOLD AND POLYMERS | HNRNPL, HNRNPLL, ACSL3 | TSHR 1764/4885ALDH1A1 883/4885HPGD 2480/4885 |
| US-20120114759-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | VEGFA, IAPP, FLT1 | TSHR 2490/4885ALDH1A1 4007/4885HPGD 1920/4885 |
| US-20180134753-A1 | BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES | VEGFA, LRRFIP1, FLT1 | TSHR 2635/4885ALDH1A1 3587/4885HPGD 3105/4885 |
| US-20180028455-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | VEGFA, IAPP, FLT1 | TSHR 2490/4885ALDH1A1 4007/4885HPGD 1920/4885 |
| US-20140294909-A1 | NANOCOMPOSITES OF GOLD AND POLYMERS | HNRNPL, HNRNPLL, ACSL3 | TSHR 1764/4885ALDH1A1 883/4885HPGD 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.